Clinical Trial Matcher

NCT07095621

Feasibility and Effectiveness of Three-day Discharge After Distal Pancreatectomy

Not Yet Recruiting · Not specified · IRCCS San Raffaele · registry updated 2025-08-07

Inclusion and exclusion lines below are quoted from ClinicalTrials.gov. No match score is shown, because a score needs a person's age, biomarkers, and treatment dates. Confirm the record with the study team.

Background: Enhanced recovery after surgery (ERAS) programs and the minimally invasive approach have significantly improved recovery outcomes following distal pancreatectomy (DP). Nevertheless, most patients stay in the hospital a median of 7 postoperative days after laparoscopic DP, despite achieving functional recovery 3-4 days earlier. Early discharge protocols have proven to be safe and feasible If selected patients. Research objectives: This study aims to evaluate the feasibility and effectiveness of a three-day discharge (3DD) protocol for patients undergoing minimally invasive DP. Study design: This is an observational, prospective cohort study that will be conducted at San Raffaele Hospital (Milan, Italy) Primary Objective: To investigate the feasibility of a 3-day discharge protocol following a minimally invasive distal pancreatectomy, with post-discharge phone follow-up conducted by a nurse navigator....

Inclusion

  • adult (age\>= 18 years) patients undergoing elective minimally invasive distal pancreatectomy
  • patients residing or with a temporary accommodation within 50 km or a 30-minute drive from the hospital;
  • patients with an adequate support system at home (defined as 24-hour support for at least the first POD7);
  • no contraindications to intrathecal or opioid-sparing analgesia;
  • patient who have signed the inform consent for participation in the trail;
  • No preoperative medical issue requiring inhospital observation longer than three days

Exclusion

  • Patients undergoing multi-visceral resection;
  • undergoing an open procedure;
  • requiring vascular resection;
  • having a history of chronic opioid use;
  • having significant comorbidities or an American Society of Anesthesiologists (ASA) score \> 3;
  • patients unabled to speak Italian;

Open NCT07095621 on ClinicalTrials.govAll conditions